BLACK PEARL COMPLETES TENDER OFFER FOR ALL OUTSTANDING SHARES OF SELECTIS HEALTH, INC.

Black Pearl Equities completed its tender offer to buy Selectis Health for $5.75 per share in cash, with the offer expiring Aug. 31, 2026. About 2,789,027 shares were validly tendered (~90.93% of outstanding shares), enabling the deal conditions to be satisfied and payment to proceed. Remaining shares will be acquired via a post-tender merger without a stockholder vote, making Selectis an indirect wholly owned subsidiary of Black Pearl.

Analysis

This is effectively a near-certain cash-out, so the only real edge is in the residual arbitrage spread, not the underlying business. With >90% already locked, the remaining value is dominated by closing mechanics and settlement timing; upside from here is capped while downside is mostly deal-friction risk, making it a low-volatility, event-driven position rather than a fundamentals trade.

The second-order effect is on other small-cap skilled nursing / assisted-living operators: this reinforces that private capital still sees value in fragmented post-acute assets, but it does not automatically re-rate public comps because the buyer is acquiring control, not paying up for a liquid minority stake. Any read-through to names like OHI, NHI, or SNF-linked operators should be muted unless we see multiple similar takeouts at materially higher implied cap rates.

The main risk is not deal economics but process: back-end minority holders can get stuck in a thin OTC name if the merger timeline slips, and any paperwork or legal delay can temporarily widen the spread. Over 1-3 months the catalyst path is binary and short; over 6-18 months the only structural implication is that private buyers remain active in healthcare real estate, which is a floor for valuations but not a reason to chase public equities.

Contrarian view: the market may already be treating this as done, so the spread could be too tight for most capital to bother. If the stock is within a few cents of $5.75, the expected value after liquidity/operational friction is poor; the better trade may be to wait for any post-announcement dislocation rather than force exposure now.

Key Decisions for Investors

• GBCS event-arb long only if the stock still trades at a meaningful discount to $5.75 cash value; target entry at >1.0% spread, with expected duration days to a few weeks and downside limited to deal-break risk or settlement friction.
• Do not initiate a new position if GBCS is already within a few cents of consideration; the remaining upside is too small relative to OTC liquidity and execution risk.
• Set a closing-risk alert on GBCS: if the spread widens materially after acceptance-for-payment, it is a better buy-the-dip arb than chasing strength; if the spread fails to tighten by month-end, assume an administrative delay rather than a new fundamental risk.
• Watch OHI and NHI as indirect beneficiaries only if more healthcare M&A prints follow; otherwise no immediate sector trade, since this transaction is too small to justify a broad public-operator re-rating.
• If you already own GBCS from lower levels, hold into cash settlement rather than selling into illiquid OTC prints unless the stock trades at a premium to implied deal value after fees.